Hunt Anthony, Chief Executive Officer, has demonstrated a clear selling bias in his recent insider trading activity, as evidenced by SEC Form 4 filings. Over the course of 53 transactions across two companies, Repligen Corporation (RGEN) and BioLife Solutions, Inc. (BLFS), Anthony’s total sell value significantly outweighs his buy value, with $24.39 million in sales compared to $3.09 million in purchases. Notably, his recent activity has been exclusively focused on selling, with 18 transactions since September 2025, all involving RGEN shares. These sales have ranged in value from $11,168.64 on September 10, 2025, to $1,758,278.96 on November 12, 2025, with several transactions exceeding $1 million in value. The largest single sale occurred on November 13, 2025, totaling $896,234.14.
Anthony’s trading pattern reveals a concentrated focus on RGEN, with no recent activity in BLFS beyond administrative filings. The absence of recent purchases further underscores his selling bias. While his transactions include a mix of market sales (code S) and exercises of derivative securities (code M), the overwhelming trend points to a reduction in his RGEN holdings. This activity aligns with his broader trading history, which has been dominated by sales, particularly in the latter half of 2025 and early 2026. The data reflects a consistent and substantial divestment strategy, though the specific reasons behind these transactions remain undisclosed.
AI-assisted summary